NCT06261320View on ClinicalTrials.gov

Mesotherapy Treatment of Irritable Bowel Syndrome

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions
Inflammatory Bowel Diseases
Interventions
DRUG

Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate

4 sessions of mesotherapy (mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate), with intra-epidermal and intra-hypodermal technics.

Trial Locations (1)

44600

Polyclinique de l'Europe, Saint-Nazaire

All Listed Sponsors
lead

Polyclinique de l'Europe

OTHER

NCT06261320 - Mesotherapy Treatment of Irritable Bowel Syndrome | Biotech Hunter | Biotech Hunter